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Abstract
Background: The effective treatment of triple-negative breast cancer (TNBC) remains a profound clinical challenge.
Despite frequent epidermal growth factor receptor (EGFR) overexpression and reliance on downstream signalling
pathways in TNBC, resistance to EGFR-tyrosine kinase inhibitors (TKIs) remains endemic. Therefore, the identification
of targeted agents, which synergise with current therapeutic options, is paramount.
Methods: Compound-based, high-throughput, proliferation screening was used to profile the response of TNBC
cell lines to EGFR-TKIs, western blotting and siRNA transfection being used to examine the effect of inhibitors on
EGFR-mediated signal transduction and cellular dependence on such pathways, respectively. A kinase inhibitor
combination screen was used to identify compounds that synergised with EGFR-TKIs in TNBC, utilising
sulphorhodamine B (SRB) assay as read-out for proliferation. The impact of drug combinations on cell cycle arrest,
apoptosis and signal transduction was assessed using flow cytometry, automated live-cell imaging and western
blotting, respectively. RNA sequencing was employed to unravel transcriptomic changes elicited by this synergistic
combination and to permit identification of the signalling networks most sensitive to co-inhibition.
Results: We demonstrate that a dual cdc7/CDK9 inhibitor, PHA-767491, synergises with multiple EGFR-TKIs
(lapatinib, erlotinib and gefitinib) to overcome resistance to EGFR-targeted therapy in various TNBC cell lines.
Combined inhibition of EGFR and cdc7/CDK9 resulted in reduced cell proliferation, accompanied by induction of
apoptosis, G2-M cell cycle arrest, inhibition of DNA replication and abrogation of CDK9-mediated transcriptional
elongation, in contrast to mono-inhibition. Moreover, high expression of cdc7 and RNA polymerase II Subunit A
(POLR2A), the direct target of CDK9, is significantly correlated with poor metastasis-free survival in a cohort of breast
cancer patients. RNA sequencing revealed marked downregulation of pathways governing proliferation,
transcription and cell survival in TNBC cells treated with the combination of an EGFR-TKI and a dual cdc7/CDK9
inhibitor. A number of genes enriched in these downregulated pathways are associated with poor metastasis-free
survival in TNBC.
Conclusions: Our results highlight that dual inhibition of cdc7 and CDK9 by PHA-767491 is a potential strategy for
targeting TNBC resistant to EGFR-TKIs.
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Background
Triple-negative breast cancer (TNBC) is a notoriously
aggressive, heterogeneous disease defined as lacking ex-
pression of oestrogen receptor (ER) and/or progesterone
receptor (PR) as well as amplification of human epider-
mal growth factor receptor 2 (HER2), respectively [1].
Although TNBC only constitutes approximately 15–20%
of breast cancer cases, it is disproportionately respon-
sible for breast cancer-associated deaths and carries a
dismal prognosis, compared with hormone receptor-
positive (HR+) breast cancers [2–4]. For patients with
HR+ breast cancer, endocrine therapy targeting ER is
available in the form of aromatase inhibitors and select-
ive oestrogen receptor modulators (e.g. tamoxifen) and
other antagonists [1]. Contrastingly, no effective targeted
therapy which exploits the molecular properties of
tumour cells exists for TNBC patients; clinical trials of
targeted agents in TNBC have been disappointing [5, 6].
Consequently, aggressive chemotherapy, radiotherapy
and surgery remain the mainstay treatments [7]. Fur-
thermore, patients who develop resistance to treatment,
or who do not respond to treatment whatsoever, follow
an aggressive clinical course characterised by metastasis
and a higher 5-year mortality post-diagnosis [8]. Further
complicating the treatment of TNBC is the degree of
genetic heterogeneity observed in this disease. By analys-
ing the gene expression profiles of TNBC cases, Leh-
mann et al. sub-classified TNBC into six different
molecular subtypes: mesenchymal (M), mesenchymal
stem-like (MSL), luminal androgen receptor-positive
(LAR), immunomodulatory (IM), basal-like 1 (BL1) and
basal-like 2 (BL2) [9]. Most importantly, these subtypes
exhibit dissimilar drug-sensitivity profiles, resulting in var-
ied clinical responses [9, 10]. The nature of TNBC clearly
necessitates a more tailored approach to treatment, one
which exploits the unique oncogenic addictions present.
For chemotherapy-resistant TNBC patients, the develop-
ment of targeted therapeutics which synergise with
current treatment options to overcome resistance is there-
fore paramount.
Epidermal growth factor receptor (EGFR; also known
as ERBB1/HER1) is often expressed at higher levels in
triple-negative tumours than in HR+ tumours [11],
though expression levels vary, with up to ~ 80% of
TNBC cases reported as being EGFR+ [12]. EGFR amp-
lification has also been reported to occur in a substantial
proportion of TNBC cases [13–15] with EGFR overex-
pression associated with a much poorer prognosis in
general [8]. Furthermore, EGF signalling is highly
enriched in the basal and mesenchymal TNBC subtypes
[9]. EGFR therefore represents a bona fide drug target in
triple-negative tumours. Various EGFR inhibitors have
been developed, most notably anti-EGFR monoclonal
antibodies (e.g. cetuximab) and EGFR-tyrosine kinase
inhibitors (EGFR-TKIs) (e.g. erlotinib, gefitinib and lapa-
tinib) [16]. Despite these efforts, EGFR-TKI single treat-
ment has performed poorly in clinical trials for TNBC
patients with advanced or metastatic breast cancer, des-
pite clear inhibition of EGFR [17, 18] suggesting bypass
inhibition of EGFR-related signalling in TNBC tumours
[19, 20]. Nonetheless, EGFR-TKIs have shown more
promising results as combination therapies in TNBC
[21], perhaps indicating that monotherapeutic inhibition
of EGFR is insufficient to shut down the myriad signal-
ling pathways responsible for promoting aberrant prolif-
eration and survival.
Here we demonstrate that multiple EGFR-TKIs syner-
gise with the dual cdc7/CDK9 inhibitor PHA-767491 in
a panel of TNBC cell lines resistant to EGFR-TKIs. This
combination inhibited cell proliferation, induced apop-
tosis and G2-M arrest and downregulated components
critical to cell cycle progression, DNA replication and
transcription, thereby reversing resistance to EGFR-
TKIs. Therefore, targeting deficiencies in regulation of
the cell cycle and DNA replication in conjunction with
transcriptional addiction downstream of growth factor
pathways may constitute a powerful therapeutic oppor-
tunity for this difficult-to-treat breast cancer subtype.
Methods
Cell culture
All cell lines were maintained in RPMI-1640 medium
(Gibco, ThermoFisher Scientific, Breda, The Netherlands)
supplemented with 10% FBS (Thermo Fisher Scientific;
10270106) and 25 IU/ml penicillin and 25 μg/ml strepto-
mycin (ThermoFisher Scientific; 15070-063). Cells were
cultured in a humidified incubator at 37 °C, 5% CO2. Cell
lines were provided by Erasmus MC Rotterdam and tested
monthly for mycoplasma using PCR.
Antibodies and kinase inhibitors
The primary antibodies against pEGFR (Y1173, #4407),
pERK1/2 (T202/Y204, #9101), ERK1/2 (#4695), pAKT
(S473, #9271), AKT (#9272), MCM2 (#3619), pRNA-II
(S2/5; #4735), RNA-II (#2629), and p-pRb (S780, # 9307)
were commercially supplied from Cell Signaling TECH-
NOLOGY®, EGFR (sc-03), pRb (sc-102), CDK4 (sc-601),
Cyclin D1 (sc-20,044) from Santa Cruz BIOTECHNOL-
OGY®, cdc7 (ab10535) and pMCM2 (S40/41; ab70371)
from Abcam® and Tubulin (T-9026) from Sigma®. Sec-
ondary antibodies included Cy5-conjugated anti-mouse
and horseradish peroxidase (HRP) anti-mouse or anti-
rabbit (Jackson ImmunoResearch). Individual kinase in-
hibitors lapatinib (S2111), gefitinib (S1025), erlotinib
(S7786) and PHA-767491 (S2742), plus the previously
described 273-kinase inhibitor library (L1200), were pur-
chased from Selleckchem® (Munich, Germany) and dis-
solved in DMSO solution at 10 mM [22]. TAK-931 and
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BAY-1143572 were purchased from MedChemExpress
(Sollentuna, Sweden).
Kinase inhibitor treatment and drug combination screen
Cells were seeded into 96-well plates at the appropriate
densities (Additional file 1: Table S1). The following day,
cells were treated with individual kinase inhibitors in
dose range as indicated. Vehicle DMSO (1:1000) was
used as control. For the kinase inhibitor library screen,
cells were screened in duplicate against the kinase in-
hibitor library containing 273 kinase inhibitors at con-
centration of 1 μM alone, or the 1 μM library inhibitors
in combination with lapatinib at 3.16 μM, since this con-
centration effectively inhibited EGFR phosphorylation in
all cell lines tested and since studies have shown that
levels of lapatinib in patient tumours vary between 1 and
12 μM depending on dosing schedule [23]. After 4-day
treatment, proliferation was evaluated by sulphorhoda-
mine B (SRB) colorimetric assay [24] and analysed by %
of control cell growth = (mean sample OD − mean 0-day
OD)/(mean control OD − mean 0-day OD) × 100. To as-
sess synergistic interaction of combined drugs, combin-
ation index (CI) analysis [25, 26] was performed, using
the formula ‘CI = (D)1/(Dx)1 + (D)2/(Dx)2’. (D)1 and
(D)2 are respective combination doses of two com-
pounds that yield an effect of 50% of proliferation inhib-
ition, with (Dx)1 and (Dx)2 being the corresponding
single doses for either compound that results in the
same effect, which is by definition the IC50 of each com-
pound. CI values less than 1 (CI < 1), equal to 1 (CI = 1)
or greater than 1 (CI > 1), indicate synergy, additivity or
antagonism, respectively.
Western blotting
Cells were seeded in 6-well plates at the appropriate
density. For stimulation/starvation assays, medium was
refreshed with serum-free medium (SFM) the following
day and cells were starved overnight. Thereafter, cells
were pre-treated with drug solutions for 4 h, then stimu-
lated with 100 ng/ml EGF (Sigma; E9644) for 5 min in
SFM. For time-course exposures to drugs, cells were
treated with drug solutions prepared in complete
medium. Cell lysates were harvested at the indicated
time points in RIPA lysis buffer with 1:100 Protease Inhibi-
tor Cocktail (Sigma; P8340). Cellular proteins were dena-
tured in sample buffer containing 10% β-mercaptoethanol,
loaded with 30 μg/lane into 7.5% polyacrylamide gels, re-
solved using SDS-PAGE and subsequently transferred to
PVDF membranes (Merck Chemicals; IPVH00010) over-
night. PVDF membranes were then blocked with 5% BSA-
TBST (Tris-buffered saline 0.05% Tween-20) and subse-
quently incubated at 4 °C overnight with appropriate pri-
mary antibodies. The following day, membranes were
incubated for 1 h with HRP- or Cy5-conjugated secondary
antibodies and chemiluminescence or fluorescence was de-
tected using the Las4000 (GE Healthcare).
Annexin-V staining
Cells were seeded overnight in 96-well μCLEAR plates
(Corning) at appropriate densities, then treated with
drug solutions at indicated concentrations. At 24, 48 or
72 h post-treatment, cells were stained with Hoechst
33258 (1:10,000) and Annexin-V (1:1000) for 45 min at
37 °C, 5% CO2 before being imaged using BD Pathway
855 Microscope (BD Biosciences). Annexin-V staining
was quantified using Cell Profiler software.
Cell cycle flow cytometry analysis
Cells were seeded in 6-well plates at the appropriate
density. Twenty-four or 48 h post-treatment, all cells
were harvested, re-suspended in ice-cold 200 μl 1 mM
EDTA-PBS and 800 μl 100% ethanol, and stored at −
20 °C before being centrifuged at 1000 rpm at 4 °C. Cells
were then re-suspended in 1 ml PBS and rehydrated for
15 min. After being spun at 1000 rpm for 5 min at room
temperature, the pellet was re-suspended in 250 μl 3
mM DAPI (Sigma, 10236276001) staining buffer
(100 μM Tris pH 7.4, 150 mM NaCl, 1 mM CaCl2, 0.5
mM MgCl2), incubated for 15 min at room temperature
in the dark, followed by filtration through 70-μm EASY-
strainer filters and analysed using FACS Conto II (BD
Biosciences). Data were analysed using FlowJo V10.
siRNA transfection
Cells were seeded in 96-well plates at the appropriate
density. For each siRNA transfection, 50 nM siGENOME
siRNAs (Dharmacon) were transfected into cells per 96-
well using INTERFERin transfection reagent (Polyplus;
409-50). The following day, the medium was refreshed.
Forty-eight hours post-transfection, cells were either
lysed for western blot to confirm knockdown or treated
with drugs for the appropriate duration as described,
then fixed for SRB proliferation assay.
Clinical evaluation of candidate target genes
The clinical relevance of cdc7, POLR2A and CDK9 was
evaluated using in-house gene expression and metastasis-
free survival data of 123 lymph node-negative, non-(neo)
adjuvantly treated, oestrogen receptor-negative (ER-neg)
primary breast cancer patients. The composition of this co-
hort is described in Additional file 2: Table S2. The clinical
relevance of synergy-related candidate genes was evaluated
using the previously described in-house as well as publicly
available gene expression and MFS data of lymph node-
negative, non-(neo) adjuvantly treated primary breast can-
cer patients, leading to a cohort of 142 triple-negative pa-
tients. Data were gathered from Gene Expression Omnibus
(http://www.ncbi.nlm.nih.gov/geo/) entries GSE2034,
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GSE5327, GSE2990, GE7390 and GSE11121, with all data
available on Affymetrix U133A chip. Raw.cel files were proc-
essed using fRMA parameters (median polish) [27] after
which batch effects were corrected using ComBat [28].
Transcriptome RNA sequencing and pathway integration
analysis
Cells were seeded overnight in 6-well plates and treated
in triplicate for 6 h with individual or combined kinase
inhibitors at indicated concentrations, or vehicle. RNA
was isolated with RNeasy Plus Mini Kit as described by
the manufacturer (QIAGEN, Cat. 74136). Transcriptome
RNA sequencing (RNA-Seq) was performed using Illu-
mina high-throughput RNA sequencing. DNA libraries
were prepared from the samples with the TruSeq
Stranded mRNA Library Prep Kit. The DNA libraries
were sequenced according to the Illumina TruSeq v3
protocol on an Illumina HiSeq2500 sequencer. Paired-
end reads of 100bp in length were generated. Alignment
was performed against the human GRCh38 reference
genome using the STAR aligner (version 2.4.2a). Mark-
ing duplicates, sorting and indexing were performed
using sambamba. Gene expression was quantified using
the FeatureCounts software (version 1.4.6) based on the
ENSEMBL gene annotation for GRCH38 (release 84).
RNA-Seq data was normalised by TMM using EdgeR’s
normalisation factor [29], followed by quantile normal-
isation and presented in Log2 fold change (Log2 FC)
scales. Genes with significant down- or upregulation
(Log2 FC ≥ |0.5|) under indicated conditions were ana-
lysed by web-based functional analysis tool Ingenuity
pathway Analysis (IPA) to visualise and annotate their
biological functions and pathways.
Statistical analyses
All statistical analyses, where appropriate, were per-
formed in GraphPad Prism software version 7.0. One-
way ANOVA multiple comparison test with Tukey’s post
hoc test was applied with p values less than 0.05 consid-
ered as statistically significant.
Results
TNBC cells are resistant to EGFR-TKIs
EGFR is expressed at higher levels in TNBC tumours com-
pared to ER-positive BC tumours (Fig. 1a); also in human
basal A and basal B TNBC cell lines, there is a higher EGFR
expression than in human luminal cell lines (Fig. 1b). There-
fore, we sought to systematically elucidate the response of
TNBC to a broad range of different EGFR kinase inhibitors.
A panel of TNBC cell lines with varying EGFR expression
(Fig. 1c was screened against 24 EGFR-TKIs (Fig. 1d).
Twelve cell lines (> 57%) could be classified as refractory to
almost all 24 EGFR-TKIs; only HCC1806 was highly sensi-
tive to most EGFR-TKIs, the remainder having variable
sensitivity to EGFR-TKIs (Fig. 1d). Next, three TNBC cell
lines highly resistant to EGFR-TKIs, Hs578T, BT549 and
SKBR7, and one sensitive cell line, HCC1806, were selected
for further evaluation. Hs578T, BT549 and SKBR7 cells were
resistant to lapatinib-mediated growth inhibition up to and
including concentrations of 3.16 μM, but superior concen-
trations (10 μM) impeded cellular proliferation (Fig. 1e).
Concordantly, lapatinib failed to significantly induce apop-
tosis in these cell lines at 3.16 μM (Additional file 3: Figure
S1a). In contrast, HCC1806 cells displayed enhanced growth
inhibition in response to lapatinib (IC50 ~ 100 nM; Fig. 1e)
with significantly increased Annexin-V apoptotic signal
(Additional file 3: Figure S1a). Regardless of their response
to lapatinib, all these cell lines maintained functional EGFR-
mediated signal transduction, with prominent phosphoryl-
ation of EGFR (Y1173) and downstream components AKT
(S473) and ERK1/2 (T202/Y204) in response to EGF stimu-
lation (Fig. 1f), indicating that resistance was not due to
the absence of a functionally intact EGFR pathway. In re-
sponse to lapatinib, EGFR phosphorylation was com-
pletely inhibited in all cell lines (Fig. 1f). However, EGF-
induced ERK activation persisted in all lapatinib-resistant
cell lines, with AKT phosphorylation also unaffected in
Hs578T and BT549 cells. These data suggest that these re-
sistant cells are capable of bypassing EGFR kinase inhib-
ition through the activation of downstream pro-
proliferative pathways. Despite the lack of impact of
EGFR-TKIs on TNBC proliferation, siRNA-mediated si-
lencing of EGFR and downstream components, including
ERK2 and FRAP1 (mTOR), led to a significant reduction
in cell proliferation, supporting the notion that TNBC
cells depend to a certain extent on EGFR-mediated signal-
ling for their proliferation (Additional file 3: Figure S1b).
Kinase inhibitor combination screening identifies a dual
cdc7/CDK9 inhibitor PHA-767491 which synergises with
lapatinib in TNBC
Next, we sought to identify compounds which synergise
with lapatinib by performing a combinatorial kinase in-
hibitor screen in Hs578T cells treated with 273 kinase
inhibitors at 1 μM with or without 3.16 μM lapatinib.
Most notably, amongst a number of compounds which
augmented the response of TNBC cells to EGFR inhib-
ition, including JAK3 inhibitor WHI-P154, AKT/PDPK1
inhibitor PHT-427, PIKfyve inhibitor YM201636, pan-
AKT inhibitor GSK690693, JAK2 inhibitor TG101348
and Aurora A/B/C kinase inhibitor PHA-680632, the
dual cdc7/CDK9 inhibitor PHA-767491 inhibited prolif-
eration by > 90% compared to control or either mono-
therapy (Fig. 2a). Subsequent dose response experiments
revealed that combinations of 1–3.16 μM PHA-767491
with 0.0316–3.16 μM lapatinib greatly enhanced inhibition
of Hs578T growth compared to either monotherapy
(Fig. 2b), indicative of synergy, whereas the synergistic
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effects of the other candidate compounds did not pass val-
idation. To confirm this interaction was not cell line-
specific, 17 TNBC cell lines were screened with a dose
range of lapatinib or PHA-767491 (0.0316–3.16 μM) or
with a dose range of lapatinib in combination with either
1 μM or 3.16 μM PHA-767491. These TNBC cell lines
were generally resistant to both monotherapies at doses
equal to or less than 1 μM, but lapatinib and PHA-767491
co-treatment strongly inhibited proliferation (Fig. 2c).
Combining lapatinib (3.16 μM) with PHA-767491 at ei-
ther 1 μM or 3.16 μM led to strong synergistic responses
in the vast majority of TNBC cell lines (with some additive
responses also evident), yielding CI values well below 1
(Fig. 2d), thus confirming the synergistic nature of this
interaction.
Dual pharmacological inhibition of EGFR and cdc7/CDK9
suppresses components of the transcriptional machinery
and DNA-replicative program
Having confirmed the synergistic effect of PHA-767491
and lapatinib on TNBC proliferation, we elucidated the
impact of co-treatment on EGFR-, cdc7- and CDK9-
mediated signalling transduction. Forty-eight hours post-
exposure, lapatinib (3.16 μM) in combination with PHA-
767491 (1 μM) reduced levels of cdc7, accompanied by
decreased phosphorylation of its downstream target
a
c
e
b d
f
Fig. 1 Resistance of TNBC cells to EGFR-TKIs. a RNA-Seq-based log2 EGFR expression levels in oestrogen receptor-positive (ER+) breast cancer (991
cases) and TNBC tumours (116 cases) derived from 1107 cases in The Cancer Genome Atlas (TCGA) database. Graphs show data distribution, the mean
and the lower and upper quartiles. Error bars represent standard deviation. b RNA-Seq-based log2 EGFR expression in basal-like and luminal-like BC cell
line subtypes (total 50 BC cell lines, in-house). Graphs show data distribution, the mean and the lower and upper quartiles. Error bars represent
standard deviation c EGFR expression in 20 TNBC cell lines. d Resistance of TNBC cells to EGFR inhibitors (EGFRi). Cells were treated with 1 μM inhibitor
for 4 days. Proliferation was assessed using sulphorhodamine B (SRB) assay. Z-score was represented by normalising raw values to those of DMSO
control. e Dose response of EGFRi-resistant TNBC cell lines (Hs578T, BT549 and SKBR7) and an EGFRi-sensitive cell line (HCC1806) to lapatinib.
Percentage of proliferation was normalised to DMSO control. Data shown as mean ± standard deviation for two independent experiments performed
in triplicate. f EGFR pathway functionality in TNBC cell lines Hs578T, BT549 and SKBR7 and HCC1806. Cells were starved for 24 h in serum-free medium,
treated with drug solutions prepared in serum-free medium for 4 h then stimulated with 100 ng/ml EGF for 5min
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MCM2 (Ser40/41), a critical component of DNA
helicase, suggesting an inhibitory effect on initiation
of DNA replication in Hs578T, BT549 and SKBR7
cells (Fig. 2e). This co-treatment also moderately de-
creased CDK9-mediated phosphorylation of Ser2/5
residues in the C-terminal domain of RNA Polymer-
ase II (RNAII), implying impairment of CDK9- and/
or CDK7-mediated productive transcriptional elong-
ation (Fig. 2e). Additionally, co-treatment with PHA-
767491 at 3.16 μM not only led to complete aboli-
tion of cdc7 levels but also depletion of total MCM2
and RNAII and their associated phosphorylated
forms, perhaps indicative of stalled RNAII-mediated
transcriptional elongation (Fig. 2e). These data suggest
that co-treatment of TNBC cells with lapatinib and the
dual cdc7/CDK9 inhibitor PHA-767491 blocks compo-
nents essential for initiation of DNA replication and RNA
polymerase II-mediated transcription.
a c
b
d
Fig. 2 Kinase inhibitor combination screening identifies compounds which synergise with EGFR-TKIs in TNBC. a EGFRi lapatinib (Lap) and kinase
inhibitor (KI) combination screen in EGFRi-resistant Hs578T cells. Cells (8000/well) were treated with 1 μM of 273 individual KIs alone, or in combination
with lapatinib at 3.16 μM, for 4 days. The dual cdc7/CDK9 inhibitor PHA-767491, one of the KIs which most strongly synergised with lapatinib, is singled
out, as indicated. b Dose response curves for Hs578T cells. Cells were treated with a dose range of PHA-767491 or lapatinib (0.0316–3.16 μM) or
lapatinib combined with 0.316, 1 or 3.16 μM PHA-767491. Data shown as mean ± standard deviation for two independent experiments. c Validation
screen of lapatinib/PHA-767491 synergistic effect in a panel of 17 TNBC cell lines, under indicated combinations. Cells were treated with dose ranges
of lapatinib or PHA-767491 (0.0316–3.16 μM) or the indicated combinations. d Combination indices (CI) for lapatinib (3.16 μM) combined with either
1 μM or 3.16 μM PHA-767491. Log CI is shown. e Initiation of DNA replication and productive transcriptional elongation in Hs578T, BT549 and SKBR7
cells treated with lapatinib and/or PHA-767491 as indicated, for 48 h. TKI refers to lapatinib at 3.16 μM
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Selective EGFR-TKIs erlotinib and gefitinib also synergise
with PHA-767491 in TNBC
To verify whether synergy between lapatinib and PHA-
767491 represents a general EGFR-TKI-related phenomenon,
TNBC cells were treated with other selective EGFR-TKIs, er-
lotinib and gefitinib [30], in combination with PHA-767491.
At a concentration of 3.16 μM, erlotinib and gefitinib inhib-
ited EGF-mediated activation of EGFR phosphorylation and
downstream phosphorylation of ERK1/2 and AKT in
Hs578T and SKBR7 cells (Fig. 3a), perhaps reflective of their
increased potency compared to lapatinib in eliciting EGFR
inhibition. However, proliferation of all cell lines tested was
refractory to erlotinib and gefitinib monotherapy up to
3.16 μM (Fig. 3b). Strikingly, at concentrations of 0.1 μM or
above, erlotinib and gefitinib strongly synergised with 1 μM
and 3.16 μM PHA-767491, almost completely inhibiting the
proliferation of Hs578T and SKBR7 cells (Fig. 3b, c). The ef-
fect of combining erlotinib or gefitinib with PHA-767491 on
DNA replication and transcription-related signal transduc-
tion largely resembled that of lapatinib combined with PHA-
767491 (Fig. 3d). Only combinations of erlotinib or gefitinib
and PHA-767491 were capable of decreasing cdc7 levels
and consequently phosphorylation of MCM2 (Ser40/41).
Similarly, inhibition of CDK9-mediated RNA-II (S2/S5)
phosphorylation was most prominent after co-treatment.
To validate the hypothesis that EGFR inhibition is critical
Fig. 3 Selective EGFR-TKIs erlotinib and gefitinib also synergise with PHA-767491 in TNBC. a Inhibitory impact of erlotinib and gefitinib on EGFR-
mediated signal transduction in Hs578T and SKBR7 cells. b Dose response of Hs578T and SKBR7 cells to gefitinib or erlotinib (0.0316–3.16 μM)
combined with 0.316, 1 or 3.16 μM PHA-767491. Data shown as mean ± standard deviation. Each graph shows one representative of two
independent experiments performed in triplicate. Combination indices (CI) of gefitinib (3.16 μM) or erlotinib (3.16 μM) with PHA-767491 (1 μM or
3.16 μM) in Hs578T, BT549 and SKBR7 cells. d Initiation of DNA replication and productive transcriptional elongation in Hs578T cells treated with
erlotinib or gefitinib and/or PHA-767491 as indicated, for 48 h. TKI refers to either erlotinib or gefitinib at 3.16 μM
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for the synergistic interaction between EGFR-TKIs and
PHA-767491, an EGFR-negative triple-negative cell line,
SUM185PE (Additional file 4: Figure S2a), was treated
with this combination. Neither AKT nor ERK1/2 was acti-
vated in response to stimulation with EGF, confirming
EGF-mediated signalling is redundant in SUM185PE
(Additional file 4: Figure S2b). As expected, lapatinib
and PHA-767491 did not synergise in EGFR-negative
SUM185PE cells (Additional file 4: Figure S2c).
Dual treatment of TNBC cells with EGFR-TKIs and PHA-
767491 induces G2/M cell cycle arrest and apoptosis
Whilst PHA-767491 at 3.16 μM inhibits cdc7 and phos-
phorylation of MCM2 and RNA polymerase II, parallel
inhibition of EGFR was necessary for eliciting a similar
effect on cell cycle components. Decreased levels of
CDK4, Cyclin D1 and phosphorylated pRb were ob-
served 48 h post-exposure to co-treatment (Fig. 4a), sug-
gesting concomitant inhibition of EGFR, cdc7 and
CDK9 obstructs cell cycle progression in TNBC cells.
Flow cytometric analysis confirmed that G2-M cell cycle
arrest occurred only when lapatinib, erlotinib or gefitinib
was combined with 3.16 μM PHA-767491 in Hs578T
and SKBR7 cells (Fig. 4b; Additional file 5: Figure S3a).
Accordingly, Annexin-V staining indicated that mono-
therapies failed to induce appreciable levels of apoptosis
in lapatinib-resistant TNBC cells, whilst combination
treatments enhanced apoptosis (Fig. 4c; Additional file 5:
Figure S3b). Subsequently, RNAi-mediated silencing of
cdc7 and CDK9 was used to dissect their respective con-
tributions to the observed synergy. siCdc7 and siCDK9
in combination with lapatinib significantly reduced
SKBR7 proliferation compared to knockdown alone,
though no sensitisation was seen in Hs578T or BT549
cells (Additional file 6: Figure S4a-b). siCdc7 or siCDK9
reduced cdc7 or CDK9 expression as well as reduced levels
of MCM2 (S40/41) phosphorylation (Additional file 6:
Figure S4c). However, neither cdc7 nor CDK9 knockdown
alone in combination with lapatinib fully recapitulated the
impact of combined lapatinib and PHA-767491 treatment
on signal transduction. Whilst MCM2 activation was
inhibited by cdc7 knockdown, minimal inhibition of
RNAII (S2/5) phosphorylation was observed after CDK9
knockdown and CDK4 levels remained constant for both
cdc7- and CDK9-depleted cells following lapatinib treat-
ment (Additional file 6: Figure S4c). Nevertheless, also
knockdown of the main off-targets of PHA-767491 did
not synergise with lapatinib (Additional file 6: Figure S4d).
As the biological effect of knockdown (e.g. depletion of
protein) and inhibition (inhibition of activity of protein)
differs, we additionally tested the highly selective cdc7 in-
hibitor, TAK-931, and CDK9 inhibitor, BAY-1143572 to-
gether with lapatinib. Whilst low concentrations of these
compounds (0.316 μM and 0.1 μM resp.) had limited
effect on proliferation, nor upon addition of lapatinib
(3.16 μM), simultaneous treatment with these cdc7, CDK9
and EGFR inhibitors strongly affected TNBC cell prolifer-
ation (Additional file 6: Figure S4e). Nevertheless, these ef-
fects were less pronounced than the combination of PHA-
767491 with lapatinib, suggesting that possibly the broad
spectrum kinase inhibitor activity of PHA-767491 contrib-
utes to the strong synergistic effect.
Expression of cdc7 and RNAII (POLR2A) is linked to poor
prognosis in breast cancer
Next, in relation to an in-house cohort of lymph node-
negative, non-(neo) adjuvantly treated 123 oestrogen
receptor-negative (ER-neg) breast cancer patients, high
expression of cdc7 was significantly associated with a
poor metastasis-free survival (MFS) (Fig. 5a). Interest-
ingly, high expression of POLR2A (RNA-II), the essential
downstream target of CDK9, was also significantly asso-
ciated with a poor metastasis-free survival in this patient
group (Fig. 5b), though CDK9 expression level was not.
Co-treatment of TNBC cells with lapatinib and PHA-
767491 inhibits crucial signalling networks and the
expression of genes linked to poor survival in TNBC
To investigate how combined EGFR-TKI and PHA-
767491 treatment distorts the global transcriptional sig-
nature of TNBC cells, we performed RNA sequencing in
Hs578T and SKBR7 cells treated with monotherapies or
combination therapy (Fig. 6a). We identified 2614 genes
upregulated by co-treatment in Hs578T cells, with 243
genes being upregulated in SKBR7 cells under the same
conditions (Fig. 6b). 1387 and 2747 genes were downreg-
ulated in co-treated Hs578T and SKBR7 cells, respect-
ively (Fig. 6b). Amongst these genes, 141 up- and 704
downregulated genes (845 transcripts) were commonly
responsive to co-treatment in both Hs578T and SKBR7
cells (Fig. 6c). Integrated pathway analysis of these 845
synergy-related genes revealed striking disturbance of
pro-proliferative pathways mediated by growth factors
such as TGF-β, EGF and insulin, as well as pathways
governing angiogenesis, stem cell pluripotency and
metastatic signalling (Fig. 6d). More specifically, an en-
richment of genes related to cell survival, viability and
migration as well as RNA transcription, cytokinesis, mi-
tosis and cell cycle progression was found amongst the
genes commonly downregulated by co-treatment
(Fig. 6e). Amongst the top biological networks downreg-
ulated as a result of combination therapy, cell survival,
transcription and cell cycle progression were particularly
prominent (Additional file 6: Figure S4). Thirty-four (2 up-
and 32 downregulated) genes out of the 845 lapatinib and
PHA-767491 co-targeted genes were significantly corre-
lated with metastasis-free survival (MFS) in 142 lymph
node-negative, non-neoadjuvantly treated TNBC patients,
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Fig. 4 EGFR-TKIs and PHA-767491 synergise to induce G2/M cell cycle arrest and apoptosis. a Inhibition of cell cycle components by co-treatment
with EGFR-TKIs (lapatinib, erlotinib or gefitinib) and PHA-767491. Hs578T and SKBR7 cells were treated with EGFR-TKI alone (3.16 μM) or combined with
PHA-767491 (1 μM or 3.16 μM) for 48 h as indicated. b Cell cycle distribution of Hs578T and SKBR7 cells after 48-h treatment with EGFR-TKIs (3.16 μM)
alone or combined with PHA-767491 (1 μM or 3.16 μM), as indicated. Data shown as mean of two independent experiments ± standard deviation. c
Induction of apoptosis by EGFR-TKI and PHA-767491 co-treatment. Hs578T and BT549 cells were treated with lapatinib (3.16 μM), PHA-767491
(3.16 μM), alone or combined, as indicated, for 24 h, 48 h or 72 h, respectively, and then stained with Annexin-V and Hoechst, followed by imaging and
image quantification. Data shown as mean ± standard deviation of two independent experiments. Relative cell death was quantified by normalising
the intensity of Annexin-V signal to that of DMSO control. One-way ANOVA ****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05
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including LMBR1L, APAF1, DDX3X and GCNT3, with
hazard ratios > 2 (Fig. 7a and Additional file 7: Table S3).
These 34 clinically relevant genes were present in the main
biological networks of apoptosis, transcription and prolifera-
tion (Fig. 7b), in which MITF, HOXC6 and ROCK2 were all
involved. MITF was defined as a regulator known to influ-
ence the levels of anti-apoptotic protein BCL-2 as well as
transcriptional regulators (ZNF114), G2/M regulators
(CDC25B), mitotic regulators (DSN1) and DNA replication/
repair proteins (TDG and PIF-1), these being downregulated
in response to MITF inhibition (Fig. 7c).
Discussion
EGFR is highly expressed in both TNBC tumours and
cell lines, supporting a role for EGFR as an oncogenic
driver in TNBC. However, clinical trials suggest single
inhibition of EGFR signalling is incapable of eliminating
TNBC cells [17, 18, 21, 31]. Consistently, our results
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Fig. 5 Expression of cdc7 and RNAII (POLR2A) is linked to poor prognosis in breast cancer patients. Metastasis-free survival curves illustrating the
relationship between expression of cdc7 or RNAII (POLR2A) and prognosis in ER-negative breast cancer patients. Curves derived from gene expression
and available survival data for 123 lymph node-negative, non-neoadjuvantly treated, ER-negative breast cancer patients at Erasmus MC Rotterdam. N =
the number of patients in the group. F = the number of patients who relapsed (distant metastasis)
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demonstrated that targeting EGFR kinase activity by
EGFR-TKIs, including lapatinib, erlotinib and gefitinib, in-
sufficiently inhibits TNBC cell proliferation, despite inhib-
ition of EGFR phosphorylation. Our kinase inhibitor
combination screen demonstrated that the dual cdc7/
CDK9 inhibitor PHA-767491 enables EGFR-TKIs to in-
hibit proliferation, induce G2-M cell cycle arrest and pro-
mote apoptosis in various TNBC cell lines expressing high
levels of EGFR. This synergistic drug interaction downre-
gulates the activity of components of the transcription
apparatus and the DNA replication programme, including
cdc7, CDK9, pMCM2 (S40/41), p-RNAII (S2/5), CDK4,
cyclin D1 and Rb, making the combination of EGFR and
cdc7/CDK9 molecular-targeted therapies promising for
this subgroup of breast cancer.
CDK9 is a member of positive elongation factor P-TEFb
and together with CDK7 is vital for gene transcription
since CDK7 and CDK9 sequentially phosphorylate the C-
terminal domain (CTD) of RNA Polymerase II (RNA II)
at Ser5/Ser7 and Ser2, respectively, allowing dissociation
a
d
b
c
e
Fig. 6 Co-treatment of TNBC cells with lapatinib and PHA-767491 inhibits crucial signalling networks in TNBC. a Global transcriptomic signature in SKBR7
and Hs578T cells after 6 h of treatment with lapatinib (3.16 μM), PHA-767491 (1 μM) or a combination of these two doses. Log2 fold change (FC)
normalised to DMSO control shown. b Venn diagrams showing the number of genes significantly (Log2 FC≥ 0.5) up- or downregulated after
monotherapy and combination therapy in Hs578T and SKBR7 cells. c Venn diagrams showing the number of genes commonly and significantly (Log2
FC≥ 0.5) up- or downregulated after combination therapy in both Hs578T and SKBR7 cells. d Top canonical pathways enriched in 845 significantly
differentially expressed genes in combination therapy as predicted by IPA online analysis. Z-score indicates activation (orange) or inhibition (blue) of the
pathway under indicated conditions, respectively. e Top bio-functions enriched in 845 significantly differentially expressed genes in combination therapy
conditions as predicted by IPA software
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of negative elongation factors and subsequent elongation
of mRNA transcripts [32–34]. Blockage of this critical
elongation step results in stalled transcription which trig-
gers ubiquitination of RNAII at active gene promoters and
its subsequent proteasome-mediated degradation [35].
Given that co-treatment with higher concentrations of
PHA-767491 reduced total levels of RNAII, investigating
whether CDK9 inhibition-mediated transcriptional stalling
is responsible for proteasome-dependent depletion of this
protein is prudent. Previous studies have demonstrated
the potential of inhibiting CDK9 in in vitro and in vivo
PDX models of TNBC using pan-CDK inhibitor dinaci-
clib, leading to G2/M cell cycle arrest and apoptosis, con-
sistent with the results presented herein [36]. CDK9 is
essential for the growth of both HR+ and TNBC cell lines,
whilst EGFR is one of many “Achilles’cluster” genes sensi-
tive to CDK7 inhibition and vital for TNBC survival [37].
Consistently, we showed that despite being resistant to in-
hibition of EGFR kinase activity by various EGFR-TKIs,
complete silencing of EGFR is detrimental to TNBC cell
growth. In addition, EGFR is capable of acting as a tran-
scription factor [38, 39]. The nuclear translocation of
EGFR is associated with resistance to chemotherapeutics
in TNBC [38, 40–42] and shields the RTK from the effects
of TKIs limited to the cell membrane, permitting EGFR to
enhance transcription of genes which govern cell cycle pro-
gression, such as Cyclin D1 and Aurora Kinase [39, 43].
Cdc7 kinase is itself indispensable for correct regulation of
cell cycle progression, exerting control over both initiation
of DNA replication and the DNA damage response [44, 45].
By phosphorylating mini-chromosome maintenance pro-
teins (MCM2-7) present in pre-replicative complexes
formed during G1 phase, cdc7 activates the helicase activity
of these proteins, leading to unwinding of DNA strands and
a
b
c
Fig. 7 RNA-Seq reveals genes linked to poor survival in TNBC which are involved in the regulation of transcription, apoptosis and proliferation. a
Thirty-four genes specifically downregulated by combination therapy whose expression is significantly correlated with metastasis-free survival in 142
lymph node-negative, non-neoadjuvantly treated, TNBC patients (data derived from in-house cohort as well as from publicly available datasets). HR
hazard ratio. b Presence of aforementioned clinically relevant, downregulated genes in the top biological networks inhibited by combination therapy.
c MITF, an upstream regulator of genes which are downregulated in response to inhibition of MITF under combination therapy
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thereby initiating DNA replication at the G1-S phase check-
point [46, 47]. It also has been reported that EGFR indirectly
influences the initiation of DNA replication by eliciting
phosphorylation of MCM7 in a Lyn kinase-dependent fash-
ion, thereby delineating possible functional overlap between
cdc7 and EGFR [48]. TNBC cells often possess p53-
inactivating mutations which abolish the DNA replication
origin activation checkpoint, rendering them susceptible to
the induction of replicative stress [49]. Induction of G2-M
arrest in our TNBC cell lines after combined inhibition of
EGFR and cdc7/CDK9 is consistent with data from other
studies which demonstrated that a p53-dependent check-
point is critical for mitigating aberrant cell cycle progression
after cdc7 depletion [50, 51].
The CDK4/Cyclin D1 complex phosphorylates Rb at
Ser780/795 thereby inactivating Rb in G1/S checkpoint regu-
lation [52, 53]. Consistently, co-inhibition of cdc7/CDK9 and
EGFR signalling in our TNBC cell lines reduces CDK4 and
Cyclin D1 levels accompanied by reduced phosphorylation
of Rb, thereby resulting in G2-M arrest and ultimately apop-
tosis. Whether the downregulation of Cyclin D1 and CDK4
by EGFR-TKIs and PHA-767491 represents a global de-
crease in the transcription of rapidly expressed, immediate
response genes due to inhibition of CDK9-mediated tran-
scriptional elongation, a decrease in the transcriptional activ-
ity of EGFR, or a by-product of the cell cycle arrest induced
by cdc7 depletion, merits further investigation. Taken to-
gether, these results identify possible functional links between
signalling downstream of EGFR and the function of both
cdc7 and CDK9, which may to some extent explain the ob-
served synergy between EGFR-TKIs and PHA-767491. Add-
itionally, silencing of cell cycle-regulatory or transcriptional
CDKs in combination with a cdc7-specific inhibitor (XL413)
in breast cancer cells has been shown to mimic the cell cycle
disruption caused by PHA-767491 [54]. Silencing of CDK9
led to negligible impact on progression of MCF10A cells
through S-phase, whilst CDK9-depleted cells treated with
XL413 accumulated in late S-phase, suggesting that the pro-
found cell cycle arrest in TNBC cells caused by PHA-767491
or cdc7 depletion may be somewhat dependent on CDK9 or
can at least be augmented by inhibiting CDK9. Nonetheless,
using RNAi-mediated silencing of cdc7 and CDK9, we were
unable to fully recapitulate the observed synergy between
EGFR-TKIs and PHA-767491 in selected TNBC cell lines.
Although PHA-767491 has off-target effects on CDK1,
CDK2 and GSK-3β which could contribute to sensitisation
of TNBC cells to EGFR-TKIs, also knockdown of these
genes had limited effects on the response to lapatinib.
Despite that triple combination of the two other selective
cdc7 and CDK9 inhibitors together with lapatinib strongly
affected proliferation in the TNBC cell lines, this effect was
not as pronounced as the combination of lapatinib with
PHA-767491. This suggests that besides cdc7/CDK9 block-
age by PHA-767491, also inhibition of other kinases likely
contributes to the observed synergy. Broad spectrum kinase
inhibition is not uncommon for highly effective anticancer
therapeutics used in the clinic. Here we have only tested the
PHA-767491/Lap combination in TNBC cell lines. Given
the broader anti-kinase activity of PHA-767491 and the side
effects of lapatinib and other EGFR inhibitors on the liver
and/or heart, further assessment of the safety of such a com-
bination treatment will be essential.
RNA-Seq transcriptomics identified genes specifically
downregulated by co-treatment with EGFR-TKIs and
PHA-767491, which were involved in pathways regulat-
ing survival, transcription and cell cycle progression.
The decreased expression of these genes (a number of
them associated with poorer MFS in TNBC) by PHA-
767491 combined with inhibition of EGFR leads to
apoptosis and downregulation of transcription and pro-
liferation. Interestingly, the transcription factor MITF
(microphthalamia-associated transcription factor), a
major upstream regulator of pathways governing apop-
tosis, proliferation and transcription, was decreased to-
gether with its downstream targets pro-survival BCL-2
and cell cycle-regulatory CDC25B as a result of combin-
ing lapatinib and PHA-767491. With regards to TNBC,
little is known about MITF’s contribution to EGFRi-
resistant phenotypes. Further research is therefore re-
quired to validate whether targeting of MITF function
constitutes a logical therapeutic avenue in TNBC, or
whether MITF inhibition is sufficient to reverse the re-
sistance of TNBC cells to EGFR-targeted therapies.
Conclusions
In summary, we show that multiple EGFR-TKIs syner-
gise with the dual cdc7/CDK9 inhibitor PHA-767491 in
various EGFR-TKI-resistant TNBC cell lines resulting in
decreased proliferation, induction of apoptosis and G2/
M cell cycle arrest. Combination therapy leads to inhib-
ition of proteins crucial for accurate DNA replication
and CDK9/RNAII-mediated gene transcription. This
combination also leads to inhibition of crucial pro-
oncogenic networks and reduces the expression of genes
linked to ERK/mTOR signalling and poor progression-
free survival in TNBC patients, perhaps identifying pos-
sible candidate genes for further research into the mech-
anism of this synergy and as therapeutic targets.
Additional files
Additional file 1: Table S1. Cell seeding densities. Densities used per
TNBC cell line for the kinase inhibitor library screening. Densities are
shown as number of cells/well in 96-well plates. (XLSX 10 kb)
Additional file 2: Table S2. Composition of in-house ER-negative breast
cancer patient cohort. (XLSX 21 kb)
Additional file 3: Figure S1. Resistance of TNBC cells to EGFR-TKIs. a. Ef-
fect of lapatinib on induction of apoptosis in selected lapatinib-resistant
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and lapatinib-sensitive TNBC cell lines. Hs578T, BT549, SKBR7 and
HCC1806 cells were treated with lapatinib (3.16 μM) as indicated, for 24 h,
48 h or 72 h, respectively, stained with Annexin-V and Hoechst, followed
by imaging and image quantification. Relative cell death was quantified
by normalising the intensity of Annexin-V signal to that of DMSO control.
One-way ANOVA **** P ≤ 0.0001, *** P ≤ 0.001, ** P ≤ 0.01, * P ≤ 0.05. b.
Impact of silencing EGFR and downstream components of EGFR signal-
ling pathway on the proliferation of Hs578T cells. Hs578T cells were trans-
fected with siRNAs targeting EGFR, ERK2 and FRAP1 as well as positive
(siKIF11) and negative controls (siGAPDH and siKinase Pool) as described
and grown for 4 days. Proliferation was then assessed using sulphorhoda-
mine B assay. Results were normalised to Kinase Pool using the % control
method as described in materials and methods. (PDF 191 kb)
Additional file 4: Figure S2. EGFR-negative TNBC cell line SUM185PE is
insensitive to co-treatment with lapatinib and PHA-767491. a. Immunofluores-
cence imaging of EGFR-positive (SKBR7) and EGFR-negative (SUM185PE) TNBC
cell lines. Cells were fixed using 1% paraformaldehyde and 0.1% Triton-X for
15min before being washed thrice with 1x PBS and blocked with 0.5% bovine
serum albumin in PBS for 30min. EGFR antibody (sc-03; Santa Cruz Biotechnol-
ogy®) was used to stain EGFR overnight at 4 °C. Fixed cells were then incu-
bated with anti-rabbit Alexa 488-conjugated secondary antibody (A11008;
Molecular Probes®) or Hoechst (nuclear stain; 1:10,000) for 1 h at room
temperature in the dark before being imaged at 20x magnification. b. Impact
of EGF stimulation on EGFR-mediated signal transduction in EGFR-negative cell
line SUM185PE. Cells were starved overnight in serum-free medium before be-
ing treated with lapatinib (3.16 μM) for 4 h and subsequently stimulated with
EGF (100 ng/ml) for 5min. Cells were then lysed and protein samples sub-
jected to SDS-PAGE and immunoblotting with indicated antibodies. c. Dose-
response experiment combining lapatinib and PHA-767491 in SUM185PE cells.
The upper graph shows the response of SUM185PE cells to lapatinib and
PHA-767491 monotherapies. The lower graph displays the proliferation of
SUM185PE cells after combining lapatinib (3.16 μM) with dose range (0.01–
10 μM) of PHA-767491. Proliferation was assessed using sulphorhodamine B
assay and results were normalised to DMSO using the % control method as
outlined in materials and methods. (PDF 525 kb)
Additional file 5: Figure S3. EGFR-TKIs and PHA-767491 synergise to in-
duce G2/M cell cycle arrest and apoptosis. a. Cell cycle distribution histograms
of Hs578T and SKBR7 cells after 48-h treatment with EGFR-TKIs (lapatinib, erloti-
nib or gefitinib at 3.16 μM) alone or combined with PHA-767491 (1 μM or
3.16 μM), as indicated. b. Induction of apoptosis by EGFR-TKI and PHA-767491
co-treatment. SKBR7 and SUM149PT cells were treated with lapatinib (3.16 μM),
PHA-767491 (3.16 μM), alone or combined, as indicated, for 24 h, 48 h or 72 h,
respectively, and then stained with Annexin-V and Hoechst, followed by im-
aging and image quantification. Relative cell death was quantified by normalis-
ing the intensity of Annexin-V signal to that of DMSO control. One-way ANOVA
****P ≤ 0.0001, ***P ≤ 0.001, **P ≤ 0.01, *P ≤ 0.05. (PDF 378 kb)
Additional file 6: Figure S4. siRNA-mediated silencing of cdc7 and/or
CDK9 in combination with lapatinib. a. Silencing cdc7 or CDK9 synergises
with lapatinib to inhibit proliferation in SKBR7 cells but not Hs578T or
BT549 cells. % proliferation 4 days post-treatment with lapatinib (3.16 μM)
or DMSO (1:1000) was normalised to Kinase Pool using % control method
outlined in materials and methods. One-way ANOVA **P ≤ 0.01, *P ≤
0.05, ns: not significant b. Effect of siCdc7 and siCDK9 double knockdown
in Hs578T cells. c. Effect of siCdc7 and siCDK9 on cdc7 and CDK9-
mediated signal transduction in Hs578T, BT549 and SKBR7 cells. Cells
were transfected with control (siKinase Pool (−)), siCDK9 or siCdc7 then
treated with lapatinib (3.16 μM) or DMSO, and lysates were extracted 48 h
post-exposure to compounds and subjected to immunoblotting. d. Anti-
proliferative effects of knockdown of off-targets of PHA-767491 in com-
bination with lapatinib (3.16 μM) or DMSO. e. Effects of selective inhib-
ition of cdc7 (TAK-931) and CDK9 (BAY-1143572) in combination with
lapatinib on proliferation of Hs578T and SKBR7 cells. (PDF 1727 kb)
Additional file 7: Table S3. 34 clinically relevant genes specifically
downregulated after co-treatment with lapatinib and PHA-767491 in
Hs578T and SKBR7 cells. (XLSX 10 kb)
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